Zhang Lina, Zhang Jing, Xu Jing, Guo Qian, Zou Yadan, Zhang Xuewu, Wang Kuanting, Shi Lianjie, Li Shengguang
Department of Rheumatology and Immunology, Peking University International Hospital, 102206, Beijing, China.
Department of Rheumatology and Immunology, Peking University People's Hospital, Beijing, China.
Clin Rheumatol. 2025 May;44(5):1999-2008. doi: 10.1007/s10067-025-07397-w. Epub 2025 Mar 18.
This study aimed to evaluate the utility of ANCA specificity as a primary criterion for classifying AAV subtypes to simplify the diagnostic process without compromising accuracy.
A retrospective cohort study was conducted involving 310 patients diagnosed with AAV between January 2015 and December 2023 across three tertiary care centers affiliated with Peking University. Patients were reclassified using three methods: the European Medicines Agency (EMA) algorithm, the 2022 American College of Rheumatology/European Alliance of Associations for Rheumatology (ACR/EULAR) criteria, and ANCA specificity-based classification. Concordance between classification systems was assessed using Cohen's kappa coefficients.
ANCA specificity-based classification demonstrated substantial to almost perfect agreement with the 2022 ACR/EULAR criteria for MPA/MPO-AAV (kappa = 0.806) and GPA/PR3-AAV (kappa = 0.663). Many patients initially classified as GPA under the EMA algorithm were reclassified as MPA when using ANCA specificity. EGPA classification remained consistent across all methods (kappa = 0.725 between EMA and ACR/EULAR), suggesting that ANCA specificity is less critical for EGPA. The use of ANCA specificity simplified the classification process, aligning closely with the underlying pathophysiology of AAV subtypes.
ANCA specificity serves as a valuable adjunct in the classification of AAV, particularly for distinguishing between MPA and GPA. Utilizing ANCA serotypes can simplify the diagnostic process, potentially facilitating earlier diagnosis and targeted treatment. For EGPA, traditional classification criteria remain effective. Incorporating ANCA specificity into clinical practice may enhance diagnostic accuracy and improve patient outcomes in AAV management. Key Points • ANCA-based classification aligns strongly with the 2022 ACR/EULAR criteria for MPA and GPA, providing a simplified diagnostic approach. • Adopting this approach can streamline the classification process, reduce invasive procedures, and enable earlier diagnosis while maintaining high concordance with established systems.
本研究旨在评估抗中性粒细胞胞浆抗体(ANCA)特异性作为区分抗中性粒细胞胞浆抗体相关性血管炎(AAV)亚型的主要标准的实用性,以简化诊断过程且不影响准确性。
进行了一项回顾性队列研究,纳入了2015年1月至2023年12月期间在北京大学附属的三个三级医疗中心诊断为AAV的310例患者。使用三种方法对患者进行重新分类:欧洲药品管理局(EMA)算法、2022年美国风湿病学会/欧洲风湿病联盟(ACR/EULAR)标准以及基于ANCA特异性的分类。使用科恩kappa系数评估分类系统之间的一致性。
基于ANCA特异性的分类与2022年ACR/EULAR标准在显微镜下多血管炎/髓过氧化物酶-抗中性粒细胞胞浆抗体相关性血管炎(MPA/MPO-AAV)(kappa = 0.806)和肉芽肿性多血管炎/蛋白酶3-抗中性粒细胞胞浆抗体相关性血管炎(GPA/PR3-AAV)(kappa = 0.663)方面显示出高度至几乎完美的一致性。许多最初根据EMA算法分类为GPA的患者在使用ANCA特异性时被重新分类为MPA。嗜酸性肉芽肿性多血管炎(EGPA)的分类在所有方法中保持一致(EMA与ACR/EULAR之间的kappa = 0.725),这表明ANCA特异性对EGPA的重要性较低。使用ANCA特异性简化了分类过程,与AAV亚型的潜在病理生理学密切相关。
ANCA特异性在AAV的分类中是一种有价值的辅助手段,特别是在区分MPA和GPA方面。利用ANCA血清型可以简化诊断过程,可能有助于早期诊断和靶向治疗。对于EGPA,传统分类标准仍然有效。将ANCA特异性纳入临床实践可能会提高AAV管理中的诊断准确性并改善患者预后。要点 • 基于ANCA的分类与2022年ACR/EULAR标准在MPA和GPA方面高度一致,提供了一种简化的诊断方法。 • 采用这种方法可以简化分类过程。,减少侵入性操作,并实现早期诊断,同时与既定系统保持高度一致性。